Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pedhc.2005.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Results of omalizumab treatment in chronic eosinophilic pneumonia: Real-life data.
Tuberk Toraks
March 2024
Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.
Introduction: Recurrences occur when corticosteroid therapy is discontinued or reduced during the treatment of chronic eosinophilic pneumonia (CEP). The probability of recurrence is once in 50% of patients and twice or more in 25%. In such instances, new treatment options are deemed necessary.
View Article and Find Full Text PDFEfficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience.
Clin Exp Dermatol
August 2024
Department of Dermatology, Hospital Doctor Peset, Valencia, Spain.
Article Synopsis
- Bullous pemphigoid (BP) is a common autoimmune blistering condition usually affecting older adults with various health issues, traditionally treated with corticosteroids, which have numerous side-effects.* -
- A study assessed the use of omalizumab, an IgE-targeting monoclonal antibody, for treating BP in patients who had previously used other therapies, finding that 83% of patients responded to the treatment.* -
- The results showed that omalizumab was well-tolerated with no reported side-effects, highlighting its potential as a safer and effective alternative for BP treatment compared to conventional therapies.*
Biological treatment for bullous pemphigoid.
Front Immunol
May 2023
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease. Topical or systemic corticosteroids are often used as the first-line treatment. However, long-term corticosteroid use may lead to significant side effects.
View Article and Find Full Text PDFSuccessful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.
Ital J Pediatr
January 2023
Department of Pediatrics, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Viale Golgi n.19, 27100, Pavia, Italy.
Article Synopsis
- Pediatric Mastocytosis is a rare disease that leads to an excess of mast cells, causing symptoms like itching and fatigue, particularly affecting children with Systemic Mastocytosis who are at high risk for severe allergic reactions.
- A child suffering from severe Systemic Mastocytosis experienced rapid improvement after being treated with Omalizumab, an anti-IgE monoclonal antibody, allowing for the withdrawal of steroid treatments and other medications.
- Omalizumab proved to be a highly effective and safe option for managing symptoms in children unresponsive to conventional therapies, demonstrating significant benefits in quality of life.
Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database.
Diagnostics (Basel)
October 2022
College of Pharmacy, Korea University, Sejong Campus, Sejong City 30019, Korea.
Introduction: Asthma is a chronic disease, characterized by reversible airway obstruction, hypersensitivity reactions, and inflammation. Oral corticosteroids are an important treatment option for patients with severe or steroid-resistant asthma. Biologics for asthma are recommended in patients with severe asthma, owing to their steroid-sparing effect as well as their ability to reduce the severity and aggravation of uncontrolled asthma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!